CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES - USD ($) $ in Thousands		Mar. 31, 2025		Dec. 31, 2024
Assets
Investments at fair value (amortized cost of $369,526 and $372,310, respectively)	[1]	$ 346,824	[2],[3]	$ 359,897	[4],[5]
Cash and cash equivalents		70,317		41,222
Restricted cash		1,706		28,580
Deferred credit facility costs		1,777		2,019
Prepaid expenses and other assets		5,724		2,979
Total assets		426,348		434,697
Liabilities
Revolving Credit Facility		88,000		88,000
2027 Notes, net		74,584		74,536
Base management fee payable		1,531		1,560
Other accrued expenses and liabilities		7,440		6,819
Total liabilities		171,555		170,915
Commitments and Contingencies (Note 7)
Net assets
Preferred stock, par value $0.01 per share (50,000,000 shares authorized; 525 shares issued and outstanding)		0		0
Common stock, par value $0.01 per share		237		237
Paid-in capital in excess of par value		351,766		351,766
Total distributable loss		(97,210)		(88,221)
Total net assets		254,793		263,782
Total liabilities and net assets		$ 426,348		$ 434,697
Shares of common stock outstanding (par value $0.01 per share and 450,000,000 shares authorized) (in shares)		23,689,363		23,689,363
Net asset value per common share (in dollars per share)		$ 10.73		$ 11.11

[1] All investments were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s board of directors (the “Board”).

[2] Non-income producing investments.

[3] The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). Unless otherwise indicated, all of the Company’s portfolio company investments are subject to restrictions on sales. As of March 31, 2025, the Company’s portfolio company investments that were subject to restrictions on sales totaled $346.8 million at fair value and represented 136.1% of the Company’s net assets. In addition, unless otherwise indicated, as of March 31, 2025, all investments are pledged as collateral as part of the Company’s revolving credit facility.

[4] Non-income producing investments.

[5] The Company generally acquires its investments in private transactions exempt from registration under the Securities Act. Unless otherwise indicated, all of the Company’s portfolio company investments are subject to restrictions on sales. As of December 31, 2024, the Company’s portfolio company investments that were subject to restrictions on sales totaled $359.9 million at fair value and represented 136.4% of the Company’s net assets. In addition, unless otherwise indicated, as of December 31, 2024, all investments are pledged as collateral as part of the Company’s revolving credit facility.